x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012063
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg46 of human GIRK2 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | KCNJ6 |
| UniProt No. | P48051 |
| Gene ID | 3763 |
| Gene Description | GIRK2 is a member of G protein-coupled inwardly rectifying potassium channel family proteins. GIRK family proteins allow potassium to flow into the cell and therefore control cellular excitability in the central nervous system, heart, and pancreas. Activation of most GIRK channels requires heterologous subunit assembly and the presence of ATP. GIRK2 is abundantly expressed in the brain, where it is involved in pain perception. It is also required for peripheral opioid-mediated analgesia. Additionally GIRK2 localizes to pancreatic β cells and regulates insulin secretion. Mutations in the KCNJ6 gene encoding GIRK2 are associated with Keppen-Lubinsky Syndrome, a rare disease characterized by severe developmental delay, facial dysmorphism, and intellectual disability. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
